A Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Efficacy of Allogeneic Human Mesenchymal Stem Cells in Patients With Metabolic Syndrome.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2018
At a glance
- Drugs Mesenchymal stem cell therapy-Longeveron (Primary)
- Indications Metabolic disorders
- Focus Therapeutic Use
- Acronyms SIRONA
- Sponsors Longeveron
- 09 Jan 2018 According to a National Institutes of Health media release, Dr. Anthony Oliva, Ph.D, will be the principle investigator of the study.
- 29 May 2017 New trial record